HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: revised NDI draft expected in 2013, MusclePharm invests, Sundial label and GMP warnings, AHPA publishes organic guidance

This article was originally published in The Tan Sheet

Executive Summary

CFSAN plans revised NDI draft in 2013; MusclePharm invests in BioZone delivery tech; Indiana kicks off anti-smurfing campaign; Sundial fails basic labeling, GMP compliance; AHPA advises supplement firms on organic rules; Naturex commits to sustainability; Targeted Medical Pharma expands into supplements.

You may also be interested in...



Time's Up For Sundial Herbs – US Firm Recalls All Products Seven Years After FDA’s Warning

FDA officials, following each Sundial Herbs response since 2013 to the agency stating that it had corrected problems identified during inspections, found continued violations on the firm’s website and in its store. Investigators purchased the firm’s products with violative claims as recently as February.

Energy Drinks Swayed By Liquid Supplement Draft Guidance After All

Monster Energy products will transition from supplement to conventional food labeling, in a sign that industry may be adapting to FDA’s draft guidance on liquid supplements that stirred controversy upon its publication in 2009.

Sliding Scale: Bar For COVID Therapeutics EUAs ‘Can Be Somewhat Variable’ – FDA’s Peter Marks

Marks appeared to use the variable EUA bar to justify what many viewed as early mistakes by FDA during COVID-19, and to emphasize the importance of physician awareness of the strength of evidence used to authorize a drug.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS124361

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel